Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 study.

Saved in:
Bibliographic Details
Title: Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 study.
Authors: Holtzman NG; National Cancer Institute, Center for Cancer Research, Bethesda, Maryland, United States., Im A; University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States., Curtis LM; Mount Auburn Hospital, Harvard Medical School, Cambridge, Massachusetts, United States., Schulz E; Medical University of Graz, Graz, Austria., Sharma R; National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, United States., Pirsl F; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States., Berman A; Immune Deficiency Cellular Therapy Program, bethesda, Maryland, United States., Ostojic A; National Cancer Institute, Center for Cancer Research, Bethesda, Maryland, United States., Magone MT; National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States., Cowen EW; National Institutes of Health, Bethesda, Maryland, United States., Mays JW; National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, United States., Comis LE; National Institutes of Health, Clinical Center, Bethesda, Maryland, United States., Joe G; National Institutes Of Health, Bethesda, United States., Peer CJ; Center for Cancer Research, NCI, Bethesda, Maryland, United States., Figg WD; National Cancer Institute, Bethesda, Maryland, United States., Rose JJ; NCI, Bethesda, Maryland, United States., El Jurdi N; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States., Pouzolles M; BCM, houston, Texas, United States., Hakim FT; National Cancer Institute, Bethesda, Maryland, United States., Taylor N; National Cancer Institute, NIH, bethesda, Maryland, United States., Pavletic SZ; National Cancer Institute, Bethesda, Maryland, United States.
Source: Blood advances [Blood Adv] 2026 May 27. Date of Electronic Publication: 2026 May 27.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025018898